Asia-Pacific emerged as a prominent hub for pharmaceutical contract manufacturing, featuring the presence of the maximum number of manufacturing facilities (47%), followed by Europe (30%) and North America (20%). Within North America, the US emerged as a prominent region, featuring the presence of the maximum number of manufacturing facilities (83%). In Europe, most of the pharmaceutical contract manufacturing facilities were established in France (16%) followed by those located in Germany (15%), Italy (14%) and Spain (10%). Within Asia Pacific and rest of the world, India emerged as the most prominent hub (66%) for pharmaceutical contract manufacturing, followed by China (13%) and Japan (7%).
For more information, please click on the following link:
The most expansion activity in this domain increased at a CAGR of 84%, during the period 2017-2020, with maximum number of the expansions (55) initiatives being undertaken by pharmaceutical contract manufacturers in 2020. It is also worth highlighting that, in 2021 (till May), 19 expansions have already been reported. Further, most of the initiatives within this domain were focused on the expansion of capacities and facilities (30% each), followed by those carried out to enhance existing capabilities (20%). It is also worth highlighting that, during the given period, pharmaceutical contract service providers have established 29 new facilities.
In order to support the expansion initiatives, CMOs have invested a total of USD 9,128 million during the period 2017-2021 in order to expand their capacities / capabilities and / or addition of new facilities. Owing to the rising demand of small molecules, the investment on expansion projects increased 124%.
